No Data
No Data
Piper Sandler Maintains Pliant Therapeutics(PLRX.US) With Buy Rating, Maintains Target Price $40
Piper Sandler analyst Yasmeen Rahimi maintains $Pliant Therapeutics(PLRX.US)$ with a buy rating, and maintains the target price at $40.According to TipRanks data, the analyst has a success rate of 39.
Pliant Therapeutics (PLRX) Gets a Buy From Piper Sandler
Bullish on Bexo: Pliant Therapeutics' Promising IPF Treatment Backed by Strong Clinical Evidence
Pliant Therapeutics Price Target Maintained With a $38.00/Share by HC Wainwright & Co.
H.C. Wainwright Maintains Pliant Therapeutics(PLRX.US) With Buy Rating, Maintains Target Price $38
H.C. Wainwright analyst Ed Arce maintains $Pliant Therapeutics(PLRX.US)$ with a buy rating, and maintains the target price at $38.According to TipRanks data, the analyst has a success rate of 42.7%
Buy Rating Affirmed for Pliant Therapeutics on Strong Bexotegrast Clinical Data and Broad Therapeutic Potential